Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
58,843,171
-
Share change
-
+12,023,736
-
Total reported value
-
$1,121,554,829
-
Put/Call ratio
-
4.1%
-
Price per share
-
$19.06
-
Number of holders
-
130
-
Value change
-
+$244,359,600
-
Number of buys
-
107
-
Number of sells
-
19
Institutional Holders of ALPINE IMMUNE SCIENCES INC - COM (ALPN) as of Q4 2023
As of 31 Dec 2023,
ALPINE IMMUNE SCIENCES INC - COM (ALPN) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
58,843,171 shares.
The largest 10 holders included
Decheng Capital LLC, RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, GREAT POINT PARTNERS LLC, Paradigm Biocapital Advisors LP, Frazier Life Sciences Management, L.P., BlackRock Inc., Cormorant Asset Management, LP, ORBIMED ADVISORS LLC, and VANGUARD GROUP INC.
This page lists
130
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.